BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23043026)

  • 1. α-1 antitrysin DAMPens GVHD.
    Reddy P
    Blood; 2012 Oct; 120(14):2780-1. PubMed ID: 23043026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation.
    Brennan TV; Lin L; Huang X; Cardona DM; Li Z; Dredge K; Chao NJ; Yang Y
    Blood; 2012 Oct; 120(14):2899-908. PubMed ID: 22760779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct oligoclonal T cells are associated with graft versus host disease after stem-cell transplantation.
    Berrie JL; Kmieciak M; Sabo RT; Roberts CH; Idowu MO; Mallory K; Chung HM; McCarty JM; Borrelli CA; Detwiler MM; Kazim AL; Toor AA; Manjili MH
    Transplantation; 2012 May; 93(9):949-57. PubMed ID: 22377792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
    Kennedy GA; Varelias A; Vuckovic S; Le Texier L; Gartlan KH; Zhang P; Thomas G; Anderson L; Boyle G; Cloonan N; Leach J; Sturgeon E; Avery J; Olver SD; Lor M; Misra AK; Hutchins C; Morton AJ; Durrant ST; Subramoniapillai E; Butler JP; Curley CI; MacDonald KPA; Tey SK; Hill GR
    Lancet Oncol; 2014 Dec; 15(13):1451-1459. PubMed ID: 25456364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing GVHD by interleukin-6 receptor blockade.
    Finke J; Zeiser R
    Lancet Oncol; 2014 Dec; 15(13):1411-1412. PubMed ID: 25456353
    [No Abstract]   [Full Text] [Related]  

  • 6. Haploidentical stem cell transplantation: the always present but overlooked donor.
    Spitzer TR
    Hematology Am Soc Hematol Educ Program; 2005; ():390-5. PubMed ID: 16304409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation.
    Michálek J; Collins RH; Hill BJ; Brenchley JM; Douek DC
    Lancet; 2003 Apr; 361(9364):1183-5. PubMed ID: 12686042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
    Huff CA; Fuchs EJ; Smith BD; Blackford A; Garrett-Mayer E; Brodsky RA; Flinn IW; Ambinder RF; Borrello IM; Matsui WH; Vogelsang GB; Griffin CA; Luznik L; Jones RJ
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):414-21. PubMed ID: 16545725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
    Penack O; Marchetti M; Ruutu T; Aljurf M; Bacigalupo A; Bonifazi F; Ciceri F; Cornelissen J; Malladi R; Duarte RF; Giebel S; Greinix H; Holler E; Lawitschka A; Mielke S; Mohty M; Arat M; Nagler A; Passweg J; Schoemans H; Socié G; Solano C; Vrhovac R; Zeiser R; Kröger N; Basak GW
    Lancet Haematol; 2020 Feb; 7(2):e157-e167. PubMed ID: 32004485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-Time PCR Analysis of Chimerism in T Cell Subsets as an Early Predictor of Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplantation.
    Guz K; Nasiłowska B; Tomaszewska A; Orzińska A; Smolarczyk-Wodzyńska J; Krzemienowska M; Hałaburda K; Przybylski M; Jędrzejczak WW; Mariańska B; Brojer E
    Ann Transplant; 2015 Dec; 20():720-8. PubMed ID: 26632547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice].
    Wang SB; Guo KY; Hu DM; Yin B
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):810-3. PubMed ID: 16793606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
    Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
    J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased immune transcript levels are correlated with acute graft-versus-host disease and cytomegalovirus response after allogeneic stem cell transplantation.
    Jaksch M; Remberger M; Mattsson J
    Transplantation; 2004 Jan; 77(2):195-200. PubMed ID: 14742980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Serenity Prayer for acute GVHD.
    Vogelsang GB
    Blood; 2012 Jan; 119(1):3-4. PubMed ID: 22223818
    [No Abstract]   [Full Text] [Related]  

  • 16. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
    Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
    Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
    Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y
    Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens.
    Pohlreich D; Vitek A; Maalouf J; Cetkovsky P
    Bone Marrow Transplant; 2006 Jan; 37(2):235-6; author reply 236-7. PubMed ID: 16284607
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag').
    von dem Borne PA; Starrenburg CW; Halkes SJ; Marijt WA; Fibbe WE; Falkenburg JH; Willemze R
    Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S27-9. PubMed ID: 19561408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of danger signals and ectonucleotidases in acute graft-versus-host disease.
    Apostolova P; Zeiser R
    Hum Immunol; 2016 Nov; 77(11):1037-1047. PubMed ID: 26902992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.